Results 141 to 150 of about 595,200 (266)

Ambulatory and silent myocardial ischemia in women with coronary microvascular dysfunction: Results from the Cardiac Autonomic Nervous System study (CANS). [PDF]

Int J Cardiol, 2020
Roy R, Aldiwani H, Darouian N, Sharma S, Torbati T, Wei J, Nelson MD, Shufelt C, Minissian MB, Li L, Merz CNB, Mehta PK.   +11 more
europepmc   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Diagnóstico no invasivo de isquemia miocárdica silente en pacientes con factores de alto riesgo coronario

Revista Cubana de Medicina, 2001
Se realizó un estudio explicativo, longitudinal y prospectivo para determinar la incidencia de isquemia miocárdica silente en 76 pacientes de ambos sexos y edades entre 30 y 60 años.
Arnoldo de la Cruz Bañobre, Leonardo Seara Ortiz, Nilia V Escobar Yéndez, Orestes González Martínez, Emilio Cobo Montero   +4 more
doaj  

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Painless Myocardial Ischemia [PDF]

Currently, numerous clinical studies by domestic and foreign cardiologists have clearly shown that the presence of silent myocardial ischemia (SMI) significantly worsens the prognosis of patients with coro-nary heart disease (CHD ...
Bakhramova, Azima Abbasovna
core  

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

ESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed, Daniel Mølager Christensen, Milan Mohammad, Christian Torp‐Pedersen, Lars Køber, Emil Loldrup Fosbøl, Tor Biering‐Sørensen, Morten Lock Hansen, Mariam Elmegaard Malik, Nina Nouhravesh, Charlotte Anderrson, Morten Schou, Gunnar Gislason   +12 more
wiley   +1 more source

Prevalence and Predictors of Silent Myocardial Ischemia in Asymptomatic Type 2 Diabetes Mellitus: A Cross-Sectional Study From North India. [PDF]

Cureus
Goyal K, Sharma D, Bansal P, Mohanty S, Gandhi M, Sharma N, Kanodia S, Sahai S.   +7 more
europepmc   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Silent Myocardial Ischemia in CKD Stage 3-5: Prevalence and Predictors. [PDF]

Cureus
Ali WB, Tariq T, Raashid Sidhu A, Anan S, Jannat S, Tayyab M, Ahmad M, Mushtaq U.   +7 more
europepmc   +1 more source